United States
Premiumsupplier
BBT594 CAS NO.882405-89-2
- Min.Order: 1 Gram
- Payment Terms: L/C
- Product Details
Keywords
- 5-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2,3-dihydroindole-1-carboxamide
- GTPL7584
- SCHEMBL12972358
Quick Details
- ProName: BBT594
- CasNo: 882405-89-2
- Molecular Formula: C28H30F3N7O3
- Appearance: Solid powder
- Application: BBT594, also called as NVP-BBT594, a d...
- DeliveryTime: 7 days
- PackAge: inquiry
- Port: inquiry
- ProductionCapacity: 10 Kilogram/Month
- Purity: 98%
- Transportation: inquiry
- LimitNum: 1 Gram
Superiority
BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently was shown to inhibit JAK2 activity (IC50= 8nM ~ 29nM in murine models). The Type II JAK2 inhibitor NVP-BBT594 also displayed potent inhibition of HCV activity (EC50< 1.5 mM). BBT594 impairs GDNF-RET signaling, a promising therapeutic target to enhance the sensitivity to aromatase inhibitor (AI) treatment and revert AI resistance in ER+ breast cancer cells. It also impairs GDNF-dependent growth of MCF7-LTED cells. #
Details
BBT594, also called as NVP-BBT594, a dihydroindole compound, originally developed as an inhibitor of wild-type and T315I-mutant BCR–ABL1, and then subsequently was shown to inhibit JAK2 activity (IC50= 8nM ~ 29nM in murine models). The Type II JAK2 inhibitor NVP-BBT594 also displayed potent inhibition of HCV activity (EC50< 1.5 mM). BBT594 impairs GDNF-RET signaling, a promising therapeutic target to enhance the sensitivity to aromatase inhibitor (AI) treatment and revert AI resistance in ER+ breast cancer cells. It also impairs GDNF-dependent growth of MCF7-LTED cells. #